What is the relationship between ageing, frailty and Parkinson’s disease?

18 September, 2019 | Posted in:

Back in June the Parkinson’s Academy hosted “Cutting Edge Science for Parkinson’s Clinicians”, an educational meeting sponsored by Bial Pharma. Now in its second year the meeting was a sell-out again and expectations were high. Chaired by Dr Peter Fletcher (Gloucestershire Hospitals NHS Foundation Trust), the meeting was designed to cater to the diverse needs and interests […]

Continue Reading »

How do dementia, psychosis and Parkinson’s disease overlap with each other?

12 September, 2019 | Posted in:

“Parkinson’s is now recognized as a multifaceted disorder, with considerable non-motor symptoms characterizing the disease course” opened Professor Iracema Leroi (Trinity College, Dublin). Neuropsychiatric symptoms in PD include dementia, psychosis, depression, anxiety, apathy and impulse control disorders, and affect >80% of people living with PD. [...]

Continue Reading »

What have we learnt from the GDNF study?

Dr Alan Whone opened his presentation of the pioneering GDNF study by answering the question posed – “We have learned a lot!”. Although the study did not meet its primary endpoint,33 many interesting findings can be realised in the data, and it would be wrong to view this study as a failure. First off, this was the first randomised clinical trial in PD using an innovative [...]

Continue Reading »

Prodromal PD – Fact or fiction?

“While the diagnosis of Parkinson’s disease (PD) remains focused on motor symptoms, the underlying pathological process clearly starts many years before these overt signs” began Dr Alastair Noyce (Queen Mary University London). In this ‘prediagnostic’ phase, a diverse range of non-motor and motor features can occur with a wealth of evidence now [...]

Continue Reading »

How can we target the disease mechanisms in Parkinson’s disease?

“There is currently a great deal of research being conducted on Parkinson’s disease. The Cure Parkinson’s Trust is involved in 17 trials and patients are desperate for information” stated Dr Simon Stott of The Cure Parkinson’s Trust. PD is a multifactorial disease, where both genetic and environmental factors are involved, and this provides a smorgasbord [...]

Continue Reading »

Non-pharmacological therapies: An evidence free zone?

Current medical management is only partially effective in controlling the symptoms and signs of Parkinson’s disease (PD). Medication mainly targets impairments related to dopaminergic lesions and is, therefore, not effective for symptoms that are largely related to non-dopaminergic lesions, such as impaired balance or dementia. Consequently, even with [...]

Continue Reading »

Double Dutch – Case presentation by Prof Bas Bloem

Using a series of cases, Professor Bastiaan Bloem (Director, Parkinson Center, Nijmegen, The Netherlands) underscored the importance of clinical observation in his daily practice. The first case was of a professional violinist whose tremor resulted in him retiring from his passion.1 Professor Bloem explained that this patient typically increased his [...]

Continue Reading »

Has Parkinson’s treatment really changed?

Back in June the Parkinson’s Academy hosted “Cutting Edge Science for Parkinson’s Clinicians”, an educational meeting sponsored by Bial Pharma. Now in its second year the meeting was a sell-out again and expectations were high. Chaired by Dr Peter Fletcher (Gloucestershire Hospitals NHS Foundation Trust), the meeting was designed to cater to the diverse needs […]

Continue Reading »

Now open for registration: Cutting Edge Science for Parkinson’s Clinicians 2019

In July 2018 the Parkinson’s Academy hosted a meeting, sponsored by Bial Pharma UK Ltd in Birmingham. ‘Cutting Edge Science for Parkinson’s Clinicians’ was designed to advance scientific insights for specialists working within Parkinson’s disease. Follow-up meeting: 25 & 26 June 2019 Macdonald Burlington Hotel, Birmingham, B2 4JQ   We are currently planning a follow-up […]

Continue Reading »